<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713841</url>
  </required_header>
  <id_info>
    <org_study_id>Samba-01</org_study_id>
    <nct_id>NCT02713841</nct_id>
  </id_info>
  <brief_title>Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes</brief_title>
  <acronym>Samba-01</acronym>
  <official_title>Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dance Biopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dance Biopharm Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the pharmacokinetic (PK) response after inhaled
      insulin administration with 3 different inhalation regimens and with subcutaneous insulin
      administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human trial investigated the optimal particle size for absorption of Dance-501,
      an aerosolized liquid human insulin for inhalation (INH).

      Twelve subjects with type 1 diabetes received an INH dose (50 IU) using an inhaler on 4
      visits and 6 U insulin lispro (LIS) sc on a separate visit to assess relative bioavailability
      (FREL) of INH. The inhaler was configured to generate insulin aerosol particles sized 3.5-4.0
      μm (low output mesh; LOM), 4.3-4.8 μm (medium output mesh; MOM) or 5.0-5.5 μm (high output
      mesh; HOM) during low inspiratory flow. To assess within subject variability, MOM was used
      twice. Pharmacokinetics (PK) were measured up to 8 hours after dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the insulin human / insulin lispro concentration-time curve from 0 to 8 hours (AUCINS,0-8h)</measure>
    <time_frame>0 to 8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>0 to 8 hours</time_frame>
    <description>Relative delivery efficiency (FREL) of inhaled human insulin (INH) compared to s.c. injected insulin lispro (LIS)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Inhaled insulin (LOM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled insulin (MOM1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled insulin (MOM2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled insulin (HOM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous insulin lispro (LIS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 6 unit dose of insulin lispro administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled human insulin (INH)</intervention_name>
    <description>recombinant human insulin administered with Adagio-01 inhaler device</description>
    <arm_group_label>Inhaled insulin (LOM)</arm_group_label>
    <arm_group_label>Inhaled insulin (MOM1)</arm_group_label>
    <arm_group_label>Inhaled insulin (MOM2)</arm_group_label>
    <arm_group_label>Inhaled insulin (HOM)</arm_group_label>
    <other_name>Dance-501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sc insulin lispro (LIS)</intervention_name>
    <description>insulin lispro administered subcutaneously</description>
    <arm_group_label>subcutaneous insulin lispro (LIS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus treated with multiple daily insulin injections or continuous
             subcutaneous insulin infusion and total daily insulin dose less than 1.2 units/kg/day.

          -  Body mass index 18.0 - 28.0 kg/m2.

          -  Hemoglobin A1c less than or equal to 9%.

          -  Forced vital capacity and forced expiratory volume in one second at least 75% of
             predicted normal values for race, age, gender and height.

          -  Fasting C-peptide less than 0.3 nmol/L.

        Exclusion Criteria:

          -  Subjects with any condition possibly affecting drug absorption from the lung, in
             particular subjects with decreased lung function or subjects taking bronchodilators or
             subjects who smoke.

          -  Active or chronic pulmonary disease.

          -  Any clinically significant major disorders other than diabetes mellitus.

          -  Decompensated heart failure at any time or angina pectoris within the last 12 months
             or acute myocardial infarction at any time.

          -  Proliferative retinopathy or severe neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Heise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

